2024 Exhibitors Search
SNK Therapeutics
| Country | Korea, South |
|---|---|
| Address | |
| Tel (Rep.) | 031-212-2666 |
| Website | http://www.snktherapeutics.com |
Company Introduction
SNK Therapeutics is a biotechnology company focused on developing innovative new therapies targeting autoimmune and inflammatory diseases. Our primary pipeline includes SK101, a treatment aimed at autoimmune diseases such as psoriasis and systemic lupus erythematosus through TLR inhibition, SK201, targeting a broad range of inflammatory diseases, including metabolic fatty liver disease and Alzheimer’s disease, via NLRP3 inflammasome inhibition, and SK301, designed to treat inflammatory conditions such as rheumatoid arthritis through TNF inhibition.
Leveraging our proprietary AI-driven drug discovery platform, SK Therapeutics accelerates the discovery and development of new therapeutic candidates, enhancing the precision and efficiency of indication expansion. Our focus on oral therapies offers a unique patient-centric advantage, as these treatments are designed for ease of use and effectiveness, contrasting with traditional injectable therapeutics.
Leveraging our proprietary AI-driven drug discovery platform, SK Therapeutics accelerates the discovery and development of new therapeutic candidates, enhancing the precision and efficiency of indication expansion. Our focus on oral therapies offers a unique patient-centric advantage, as these treatments are designed for ease of use and effectiveness, contrasting with traditional injectable therapeutics.
Promotional video
Exhibit Item
SNK Therapeutics is a biotechnology company dedicated to the development of innovative new drugs targeting autoimmune and inflammatory diseases. The company’s flagship pipeline includes SK101, a small molecule therapy targeting autoimmune diseases such as psoriasis and systemic lupus erythematosus through TLR inhibition. Another pipeline asset, SK201, focuses on inflammatory diseases like metabolic fatty liver disease and Alzheimer’s, utilizing NLRP3 inflammasome inhibition. SK301 targets rheumatoid arthritis and other inflammation-related diseases through TNF inhibition, with promising results in animal models. Employing an AI-driven drug discovery platform, SK Therapeutics accelerates the discovery and expansion of indications, improving the efficiency and accuracy of drug development.
Exhibit Item Images
-
Product Name : Autoimmune Disease TherapeuticsETI60 and ETI41 are innovative drug candidates targeting the treatment of autoimmune diseases. Experimental results show that they have higher efficacy and safety at lower doses compared to the existing drug Hydroxychloroquine when targeting lupus disease.
Exhibit Description
SK Therapeutics’ primary pipeline includes innovative therapeutics ETI60 and ETI41, along with SK201 and SK301 (SK101), designed to address autoimmune and inflammatory diseases. SK101 targets TLR to manage autoimmune responses. SK201 inhibits the NLRP3 inflammasome. SK301 works as a TNF inhibitor.
Co-Exhibitor or Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.